• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

VisionBlue staining solution receives FDA approval

Article

Kingston, NH—The FDA has approved D.O.R.C. International/Dutch Ophthalmic USA's New Drug Application for its patented VisionBlue staining solution for use in cataract surgery.

Kingston, NH-The FDA has approved D.O.R.C. International/Dutch Ophthalmic USA's New Drug Application for its patented VisionBlue staining solution for use in cataract surgery.

VisionBlue allows excellent visualization of the capsulorhexis in eyes with mature cataract or narrow pupils and provides a clear outline of the capsulorhexis rim during surgery.

The solution is sold in ready-to-use syringes and no mixing is required. It is available in sterile packs of 10 syringes of 0.5 ml per box. It has been available in Europe, Latin America, Asia, and Australia since 1999.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.